These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 7237422

  • 1. Macrophage-induced enhancement of endogenous tumor lysosome activity.
    Urban JL.
    Cancer Res; 1981 Jun; 41(6):2221-9. PubMed ID: 7237422
    [Abstract] [Full Text] [Related]

  • 2. Morphological evidence for the translocation of lysosomal organelles from cytotoxic macrophages into the cytoplasm of tumor target cells.
    Bucana C, Hoyer LC, Hobbs B, Breesman S, McDaniel M, Hanna MG.
    Cancer Res; 1976 Dec; 36(12):4444-58. PubMed ID: 187323
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of target recognition and destruction in macrophage-mediated tumor cytotoxicity.
    Adams DO, Johnson WJ, Marino PA.
    Fed Proc; 1982 Apr; 41(6):2212-21. PubMed ID: 6804274
    [Abstract] [Full Text] [Related]

  • 4. Differences in antibody-dependent cellular cytotoxicity and activated killing of tumor cells by macrophage cell lines.
    Ralph P, Nakoinz I.
    Cancer Res; 1981 Sep; 41(9 Pt 1):3546-50. PubMed ID: 6973392
    [Abstract] [Full Text] [Related]

  • 5. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
    Han X, Wilbanks GD, Devaja O, Ruperelia V, Raju KS.
    Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
    [Abstract] [Full Text] [Related]

  • 6. Differential sensitivity of tumor targets to liver macrophage-mediated cytotoxicity.
    Gardner CR, Wasserman AJ, Laskin DL.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6686-91. PubMed ID: 3119198
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the in vitro cytolytic effect of hepatic, splenic and peritoneal macrophages from glucan-treated mice on sarcoma M5076.
    Sherwood ER, Williams DL, Di Luzio NR.
    Methods Find Exp Clin Pharmacol; 1986 Mar 15; 8(3):157-61. PubMed ID: 3713379
    [Abstract] [Full Text] [Related]

  • 8. Predisposition of [125I]5-iodo-2'-deoxyuridine-labeled normal and neoplastic mouse fibroblasts to lysis by normal macrophages.
    Evans R, Eidlen DM.
    J Natl Cancer Inst; 1983 Nov 15; 71(5):983-9. PubMed ID: 6580500
    [Abstract] [Full Text] [Related]

  • 9. Enhancement of macrophage-induced cytotoxicity by phorbol ester tumor promoters.
    Laskin DL, Laskin JD, Kessler FK, Weinstein IB, Carchman RA.
    Cancer Res; 1981 Nov 15; 41(11 Pt 1):4523-8. PubMed ID: 7306973
    [Abstract] [Full Text] [Related]

  • 10. In vivo activation of nude mouse macrophages by human melanoma cells.
    Benomar A, Gerlier D, Doré JF.
    J Natl Cancer Inst; 1987 Jul 15; 79(1):131-6. PubMed ID: 3474441
    [Abstract] [Full Text] [Related]

  • 11. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2.
    Alleva DG, Burger CJ, Elgert KD.
    J Immunol; 1994 Aug 15; 153(4):1674-86. PubMed ID: 8046239
    [Abstract] [Full Text] [Related]

  • 12. Specific and nonspecific antitumor immunity. II. Macrophage-mediated nonspecific effector activity induced by BCG and similar agents.
    Germain RN, Williams RM, Benacerraf B.
    J Natl Cancer Inst; 1975 Mar 15; 54(3):709-20. PubMed ID: 1091741
    [Abstract] [Full Text] [Related]

  • 13. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection.
    Tsung K, Dolan JP, Tsung YL, Norton JA.
    Cancer Res; 2002 Sep 01; 62(17):5069-75. PubMed ID: 12208763
    [Abstract] [Full Text] [Related]

  • 14. Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570).
    Liepins A, Nowicky JW.
    Drugs Exp Clin Res; 1996 Sep 01; 22(3-5):103-13. PubMed ID: 8899312
    [Abstract] [Full Text] [Related]

  • 15. Tumor-associated macrophages of mouse mammary tumors. I. Differential cytotoxicity of macrophages from metastatic and nonmetastatic tumors.
    Loveless SE, Heppner GH.
    J Immunol; 1983 Oct 01; 131(4):2074-8. PubMed ID: 6619548
    [Abstract] [Full Text] [Related]

  • 16. Heterogeneity in the sensitivities of the 13762NF rat mammary adenocarcinoma cell clones to cytolysis mediated by extra- and intratumoral macrophages.
    North SM, Nicolson GL.
    Cancer Res; 1985 Apr 01; 45(4):1453-8. PubMed ID: 3978611
    [Abstract] [Full Text] [Related]

  • 17. Destruction of murine lymphoma cells by allogeneic peritoneal macrophages in vitro: influence of antiserum.
    Dingemans KP, Pels E, van Dongen G, den Otter W.
    J Natl Cancer Inst; 1983 Jan 01; 70(1):181-92. PubMed ID: 6571913
    [Abstract] [Full Text] [Related]

  • 18. Cytokinetics of macrophage-mediated cytotoxicity.
    Normann SJ, Cornelius J.
    Cancer Res; 1984 Jun 01; 44(6):2313-9. PubMed ID: 6426778
    [Abstract] [Full Text] [Related]

  • 19. Differential sensitivity of metastatic versus nonmetastatic mammary tumor cells to macrophage-mediated cytostasis.
    Yamashina K, Fulton A, Heppner G.
    J Natl Cancer Inst; 1985 Oct 01; 75(4):765-70. PubMed ID: 3862907
    [Abstract] [Full Text] [Related]

  • 20. Macrophage-mediated, antibody-dependent destruction of tumor cells in DBA/2 mice: in vitro identification of an in situ mechanism.
    Key M, Haskill S.
    J Natl Cancer Inst; 1981 Jan 01; 66(1):103-10. PubMed ID: 7005500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.